Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of safety and efficacy of NA-831 in combination with aducanumab in early Alzheimer's disease

Next Previous
Trial Profile

A phase 2 study of safety and efficacy of NA-831 in combination with aducanumab in early Alzheimer's disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Traneurocin (Primary) ; Aducanumab
  • Indications Alzheimer's disease
  • Focus Therapeutic Use

Most Recent Events

  • 09 Oct 2023 New trial record
  • 05 Oct 2023 According to a Biomed Industries media release, company will be presenting clinical protocol of this study the Clinical Trials on Alzheimer's Disease (CTAD) International Conference 2023 from October 24-27 in Boston.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top